Literature DB >> 17545532

Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.

Carla M M Prado1, Vickie E Baracos, Linda J McCargar, Marina Mourtzakis, Karen E Mulder, Tony Reiman, Charles A Butts, Andrew G Scarfe, Michael B Sawyer.   

Abstract

PURPOSE: Evidence suggests that lean body mass (LBM) may be useful to normalize doses of chemotherapy. Data from a prospective study were used to determine if the highest doses of 5-fluorouracil (5-FU) per kilogram LBM would be associated with dose-limiting toxicity in stage II/III colon cancer patients treated with 5-FU and leucovorin. EXPERIMENTAL
DESIGN: Toxicity after cycle 1 was graded according to National Cancer Institute Common Toxicity Criteria, version 2.0. Muscle tissue was measured by computerized tomography. An extrapolation to the LBM compartment of the whole body was employed.
RESULTS: Mean values of 5-FU/LBM of the entire population were different in terms of presence or absence of toxicity (P = 0.036). A cut point of 20 mg 5-FU/kg LBM seemed to be a threshold for developing toxicity (P = 0.005). This observation was pertinent to women (odds ratio, 16.73; P = 0.021). Women in this study had a relatively low proportion of LBM relative to their body surface area.
CONCLUSION: Our study shows that low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area. We conclude that variation in toxicity between females and males may be partially explained by this feature of body composition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545532     DOI: 10.1158/1078-0432.CCR-06-3067

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  159 in total

1.  Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma.

Authors:  Barbra S Miller; Kathleen M Ignatoski; Stephanie Daignault; Ceit Lindland; Megan Doherty; Paul G Gauger; Gary D Hammer; Stewart C Wang; Gerard M Doherty
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

2.  Cachexia in pancreatic cancer: new treatment options and measures of success.

Authors:  Kenneth C H Fearon; Vickie E Baracos
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

3.  Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.

Authors:  Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Grant R Williams; Kirsten A Nyrop; Karteek Popuri; Seul Ki Choi; Hyman B Muss
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

4.  High-intensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis.

Authors:  Hendrik Mugele; Nils Freitag; Jannik Wilhelmi; Yanxiang Yang; Sulin Cheng; Wilhelm Bloch; Moritz Schumann
Journal:  J Cancer Surviv       Date:  2019-02-26       Impact factor: 4.442

5.  Muscle depletion and the prediction of chemotherapy toxicity.

Authors:  Maurizio Muscaritoli; Alessio Molfino; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2013-06-11       Impact factor: 3.397

6.  Hepatic alterations during the development and progression of cancer cachexia.

Authors:  Megan E Rosa-Caldwell; Jacob L Brown; David E Lee; Michael P Wiggs; Richard A Perry; Wesley S Haynie; Aaron R Caldwell; Tyrone A Washington; Wen-Juo Lo; Nicholas P Greene
Journal:  Appl Physiol Nutr Metab       Date:  2019-10-16       Impact factor: 2.665

7.  Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.

Authors:  Daphne Y Xiao; Suhong Luo; Katiuscia O'Brian; Arun Ganti; Peter Riedell; Kristen M Sanfilippo; Ryan C Lynch; Weijian Liu; Kenneth R Carson
Journal:  Am J Hematol       Date:  2016-07-22       Impact factor: 10.047

Review 8.  Cachexia in patients with oesophageal cancer.

Authors:  Poorna Anandavadivelan; Pernilla Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

9.  Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres.

Authors:  M Pressoir; S Desné; D Berchery; G Rossignol; B Poiree; M Meslier; S Traversier; M Vittot; M Simon; J P Gekiere; J Meuric; F Serot; M N Falewee; I Rodrigues; P Senesse; M P Vasson; F Chelle; B Maget; S Antoun; P Bachmann
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

10.  Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.

Authors:  James P Carroll; Melinda M Protani; Linda Nguyen; Matthew E Cheng; Mike Fay; Mohamed Saleem; Praga S Pillay; Euan Walpole; Jennifer H Martin
Journal:  Med Oncol       Date:  2014-02-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.